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A majority of guinea pigs, each with a growing syngeneic tumor implant in the
skin and no other outward sign of malignancy (clinical stage I disease) but with tumor
cells in the regional lymph nodes, was cured by tumor-specific immunization after
limited surgery consisting of excision of the dermal tumor (1, 2). Animals treated by
limited surgery alone were not cured; they developed palpable tumors in the draining
lymph nodes, and at autopsy, 70-80% of the animals were found to have pulmonary
metastases (3). We now report the results of studies to test the efficacy of limited
surgery and tumor-specific immunization in the treatment of animals, each with a
dermal tumor and a palpable draining lymph node (clinical stage II disease) . We also
tested limited surgery and immunization for the treatment of animals with clinical
stage II disease and pulmonary tumors that had been implanted intravenously.
Information from these studies may be useful in the design of clinical investigations
to evaluate proposed treatments for humans with cancer.
Materials and Methods
Animals.
￿
Male Sewall Wright strain 2 guinea pigs 3-4 mo old and weighing 500-550 grams
were obtained from the Laboratory Aids Branch, Division of Research Services, National
Institutes of Health (NIH) Bethesda, Md. andfrom the Experimental Animal Breeding Facility
of the National Cancer Institute, Frederick Cancer Research Center, Frederick, Md. Caged in
groups of six, the animals were maintained on a diet of NIH guinea pig ration and filtered tap
water, which were available to the animals at all times.
Tumor Line. We used a transplantable, syngeneic hepatocellular carcinoma-designated
line 10 (L10)'-in transplant generations 9-19. This diethylnitrosamine-induced tumor has
been converted to ascites form and is passed intraperitoneally in weanling strain 2 guinea pigs.
Inoculation of 106 L10 tumor cells intradermally in the flank 2 cm posterior to the axillae of
animals that are left untreated leads to progressive intradermal tumor growth, metastasis of
tumor cells to draining lymph nodes, and death. At autopsy, 30-40% of the animals are found
to have gross, visiblepulmonary metastases (3). Limited surgery designed to remove the dermal
tumor and to leave microscopic lymph node metastases in place is not curative, but prolongs
survival of the guinea pigs; at autopsy, the majority of them are found to have pulmonary as
well as lymph node metastases (3).
Lymph Nodes.
￿
In the descriptions that follow, the lymph noes are listed in the orderof their
* Supported by grant 7820 from the Cancer Research Institute, Inc., New York.
' Abbreviations used in this paper: BCG, bacillus Calmette-Guerin; BCG CW, cell walls of BCG; 1,10, line
10 syngeneic, hepatocellular carcinoma; FRA, first rib axillary; PA, proximal axillary; SDA, superficial
distal axillary; SDC, superficial dorsal cervical.
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drainage pattern. The superficial distal axillary (SDA) lymph node is the lymph node closest
to the intradermal tumor and is located in a fat pad posterior to the humeral scapular joint
superficial to thelatissimus dorsi muscle and in an angle describedby the triceps brachii muscle
ventrocranially and the trapezius muscle dorsocaudally. The proximal axillary (PA) lymph
nodes are in a fat pad at the apex of the axilla alongside the axillary vein at the caudomedial
border of the teres major muscle, near the insertion of the latissimus dorsi muscle. The first rib
axillary (FRA) lymph node is ventral to the first riband dorsal to thepectoral muscles near the
termination of the first rib and dorsal to the pectoral muscles near the termination of the
axillary vein. The superficial dorsal cervical (SDC) lymph node is in a fat pad immediately
anterior to the cranial border of the scapula. The superficial inguinal lymph nodes are located
just beneath the skin at thejunction of the abdomen and medial aspect of the hindlimb (4).
Staging.
￿
A staging system was devised based on similar systems in use for human cancer.
Animals with established intradermal tumors and palpable axillary metastases, but without
gross evidence of distant metastases, were considered to be at clinical stage II. In some
experiments, pulmonary tumor deposits were established by intravenous injection of 1 ml of a
suspension of L10 cells into the lateral vein of the penis of guinea pigs anesthetized with
methoxyflurane (Metafane; Pitman-Moore, Inc., Washington Crossing, N. J.) .
Preparation of Cell Walls ofMycobacterium bovis, Strain Bacillus Calmette-Gderin (BCG CW) in Oil-
in-Water Emulsion. BCG CW (lots 286 and 276), prepared as described previously (5), were
obtained from Dr. Edgar Ribi (Rocky Mountain Laboratory, Hamilton, Mont.). Oil-in-water
emulsions of BCG CW were prepared as described (1) to contain (per ml) 1.87 mg BCG CW,
30 Al oil, and 2 F,1 Tween 80.
Irradiation.
￿
L10 tumor cells (3 X 10'/ml) were irradiated with a dose of 10,000 rad gamma
("'Csor 'Cc) or x radiation. The cells were centrifuged and resuspended in fresh medium 199
to aconcentration of 62.5 X 106 cells/ml. After irradiation, the concentration and viability of
the cells were determined by the trypan blue exclusion test; no decrease in viability was
observed after irradiation. No ascites tumors formed after intraperitoneal injection of 106
irradiated L10 cells.
Tumor Cell and Adjuvant Mixture. Irradiated tumor cells and BCG CW were prepared
immediately before use. A suspension of washed, irradiated L10 cells (5.0 X 108 cells) was
centrifuged at 140 g in a 17- X 100-mm polypropylene test tube (2059; Falcon Labware, Div.
Becton, Dickinson & Co., Oxnard, Calif.), and the cell pellet was resuspended by dropwise
addition of 2 ml of BCG CW emulsion with continuous mixing.
Limited Surgeryfor Stage IIDisease.
￿
Guinea pigs were anesthetized by intraperitoneal injection
of sodium pentobarbital (30 mg/kg) supplemented with inhalation of methoxyflurane. The
dermal tumor in each animal was excised with a 1-cm margin of skin; the SDA lymph node
and all of the associated fat pad were dissected free from underlying tissues and removed.
Hemostasis was maintained with cautery, and the incision was closed with closely spaced metal
wound clips.
Extensive Surgery .
￿
In some experiments, the dermal tumor, fore limb, and scapula including
the SDA and PA lymph nodes were removed in one piece. In addition, the FRA and SDC
nodes were removed by dissection. Hemostasis was maintained by ligation with 4-0 silk and
cautery. The surgical wounds were irrigated by washing with a solution of cephaloridine (Eli
Lilly &Co., Indianapolis, Ind.) containing 2 mg of antibiotic/ml of phosphate-buffered saline,
and the incision was closed with closely spaced wound clips.
Immunotherapy. I or 2 d after surgery and again 6 or 7 d later, animals received four
intradermal injections each time of a mixture of irradiated tumorcells (2.5 X 10' per injection
site) and adjuvant (188 Fig BCG CW per injection site) . Injections were given in the flank in a
line extending from back to belly. The first treatment was given on the left (ipsilateral) flank
and the second on the contralateral flank 7 d after the first. The ipsilateral injections were
givenso that one injection site was above the incision line, onewasjust below the incision line,
and two were in the axilla. Contralateral injections were made along a vertical line ^-2.5 cm
posterior to the SDA lymph node. Each animal received a total of 2 X 108 irradiated tumor
cells and 1,500 jug of BCGCW.
Detection of Living Tumor Cells in Lymph Nodes.
￿
Lymph nodes were disaggregated in medium
199 by mincing them with scalpel blades. Each disaggregated lymph node was transferredHUNTER ET AL.
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quantitatively to an individual weanling strain 2 male recipient by i.p . injection though a 13-
gauge trocar . The presence of tumor cells in the donor lymph node was indicated by the
progressive growth of ascites tumor in the recipient . A single, living L10 ascites tumor cell
injected intraperitoneally will multiply and the recipient will die within ^-42 d (J . T. Hunter,
unpublished observations) .
Measurements.
￿
Animals were examined at weekly intervals after surgery to detect growth of
tumors. Measurements were made of the size ofPA lymph nodes, because this was invariably
the first site of palpable tumor growth after limited surgery for clinical stage II disease . For 3-
4wk after immunization, it was not possible to distinguish between lymphadenopathy resulting
from immunostimulation and that resulting from tumor growth . Enlargement ofthe PA lymph
nodes detected 4 wk after immunization was a reliable indicator of tumor progression . Animals
with disease remaining after surgery died 60-90 d after tumor cell injection with widespread
lymph node metastases (axillary, inguinal, and cervical lymph nodes) and anasarca . At autopsy,
about one-half of the animals were found to have pulmonary metastases as a consequence of
the dermal implant . There were no recurrences of tumors at the site of excision . The date of
death was recorded . The animals were observed for a minimum of 120 d after injection of
tumor cells .
Statistics .
￿
The significance of differences in tumor incidence was assessed with the Fisher
exact test (one tailed) . Differences in survival time were assessed with the Mann-Whitney U
test .
Results
Stage II Metastatic Tumor: Spread of Disease and Host Immunity .
￿
In two experiments,
106 L10 tumor cells were injected i.d . into each of 11 guinea pigs . 19-20 days later,
when the dermal tumors had grown to an average diameter of 11 .3 f 0.4mm and the
draining SDA lymph nodes were palpable with an average diameter of 6.2 ± 1 .0 mm,
animals were killed and the draininglymph nodes beyond the SDA were excised from
each animal . Each lymph node was minced and transferred intraperitoneally to a
normal weanling guinea pig . 10 of the 11 excised PA, 2 of 11 FRA, and 1 of 11 SDC
lymph nodes were found to contain living tumor cells . Another group of 12 guinea
pigs with clinical stage II disease was treated by excision of the dermal tumor and the
palpable draining lymph node, and the next day, each of them as well as control
animals received an intradermal challenge of 105 L10 tumor cells . Controls were 12
animals with stage II disease not treated by surgery and 7 animals that received no
tumor initially and no surgery . 9 of the 12 animals treated by limited surgery, 3 ofthe
12 animals not treated by surgery, and none of the seven normal controls rejected the
tumor challenge . All 10 animals in a group treated by extensive surgery were cured,
and 6 ofthem rejected the dermal tumor challenge (Table I) .
The results of these experiments indicated that when palpable lymph node metas-
tases developed in the SDA lymph node, tumor cells were present in the PA lymph
nodes, and to a lesser extent in more distant lymph nodes . Though some degree of
anti-tumor immunity was generated at or after the time of challenge, it was evidently
insufficient to prevent the progressive growth of micrometastases remaining after
limited surgery.
Postsurgical Immunotherapy for Stage II Disease: Micrometastases in the PA Lymph
Nodes . We have previously shown that micrometastases in the SDA lymph nodes
(i.e ., clinical stage I disease) could be eradicated by excision of the primary tumor
followed by a single immunization with living tumor cells plus BCG CW (1, 2) .
Preparations containing 30 X 106 live L10 cells that were reproducibly effective in
treating micrometastases in SDA nodes of guniea pigs with stage I disease (2)256
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TABLE I
Effect of Surgery on Tumor Transplantation Immunity and the Development of Progressing Lymph Node
Metastases
* Animals were challenged on day 22 with 105 syngeneic tumor cells intradermally (i.d.) on the contralateral
flank.
f Number rejecting challenge in group 2 vs. number rejecting challenge in group 1 significantly different
(P = 0.04).
significantly prolonged survival of animals with stage 11 disease, but were ineffective
in preventing growth of PA node metastases (results not shown) . The incidence of
tumors growing at the immunization site (12/24) was higher than we found with
identical preparations used to treat less advanced (stage 1) disease (2).
Preparations containing irradiated L10 and BCG CW were reproducibly effective
for treatment of animals with residual stage I disease and were not tumorigenic (2) .
This approach was used to treat PA lymph node metastases remaining after limited
surgery for stage 11 disease, with the difference that two treatments were given: the
first on the ipsilateral flank followed 1 wk later by a booster treatment on the
contralateral flank. This treatment prevented growth of residual lymph node metas-
tases in 29 of 38 animals treated (Fig. 1 A and B) . In the groups treated by surgery
alone (excison of the primary tumor and SDA lymph node), metastases in the PA
node grew in all but 2 of the 30 animals, and more than one-half of the animals had
pulmonary metastases at death.
Immunotherapy of Animals with Intravenously Implanted Microscopic Tumor Deposits in the
Lung. Microscopic tumor deposits established in the lungs of healthy animals by
intravenous injection of L10 cells could be eradicatedby immunization with a mixture
of irradiated L10 cells and live BCG (6). Preparations containing irradiated L10 and
BCG CW instead of living bacteria were also effective in preventing the growth of
these micrometastases. Two treatments were given, the first on the left flank 2 d after
intravenous injection of the L10 cells, and the second on the right flank 1 wk after the
first treatment. Treatment with a preparation containing 108 irradiated L10 cells and
750 jig of BCG CW protected animals that had received 104, 105, or 106 L10 cells i.v.
(Fig. 2 A, B, and C). Significant protection and prolongation of survival was obtained
even when treatment was delayed for as much as 7 d after injection of 106 L10 cells
intravenously (Fig. 3) .
Immunotherapy of Animals with Lymph Node Micrometastases and Intravenously Implanted
Microscopic Pulmonary Tumor Deposits. The efficacy of limited or extensive surgery with
or without active specific immunization was evaluated in animals with clinical stage
II disease, with and without the added burden of pulmonary tumor deposits implanted
Group Day 0 Surgery (day 21)
Number with
PA lymph
node metas-
tases/total
Number re-
jecting tumor
challenge/
total*
1 L10 i.d. None 12/12 3/12
2 L10 i.d. Excision of primary tumor and SDA 12/12 9/12$
lymph node
3 L10 i.d. Excision of primary tumor, SDA, PA, 0/10 6/10
FRA, and SDC lymph nodes, and
forelimb
4 Nothing None - 0/7to
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FIG. I.
￿
Postsurgical immunotherapy ofanimals with occult metastases in the second draining (PA)
lymph node in two experiments (A and B) . All animals received 106 L10 cells intradermally on day
0. The dermal tumor and palpable SDA lymph node were excised on day 19 (A) or 20 (B). ", no
postsurgical treatment. O, intradermal injection of 750 jig BCG CW + 108 irradiated L10 cells
ipsilaterally 2 d after surgery followed 7 d later by contralateral treatment with the same vaccine.
The fractions indicate the number of animals alive and tumor free/number treated.
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i.v. on the day of surgery. The data presented in Table II show the following: In
animals with regional disease and no intravenously implanted tumor: (a) All animals
treated with limited surgery died with extensive lymph node metastases, and a
majority had grossly evident lung metastases. (b) Extensive surgery cured a significant
proportion of the treated animals. (c) Limited surgery plus active immunization also
cured a significant proportion oftreated animals. Active specific immunotherapy plus
limited surgery was no more effective than extensive surgery. In animals with regional
disease and intravenously implanted pulmonary tumor: (a) Animals treated either by
limited or extensive surgery died. (b) A significant proportion of animals treated by
active immunization after limited or extensive surgery survived.
The purpose of these experiments was to develop an immunization procedure to
eliminate occult metastases in lymph nodes and viscera. Such metastases may be
present in cancer patients after all the detectable tumor has been removed surgically.
If a systemic specific immune response to the tumor could be generated by active
immunotherapy, malignant cells not removed at surgery might be eliminated. Several
animal models have been used to demonstrate the efficacy of immunization with
tumor cell vaccines in the treatment of animals with subcutaneous, intradermal, or
intravenous transplants of live tumor cells (3, 7-10). Living bacillus Calmette-Guerin
(BCG) as well as BCG CW on oil droplets have been shown to be effective adjuvants
in generating systemic immunity to L10 (2, 6, 7, 11) . In this and previous reports, we
have used the L10 tumor as a model for postsurgical immunotherapy of animals with
lymph node metastases. In thosestudies, BCG CW on oil droplets was found to be an
effective adjuvant (1, 2) .258
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Ftc. 2. Therapy of pulmonary tumor deposits with vaccines containing irradiated L10 cells.
Animals received 10" (A), 105 (B), or 106 (C) LIO cells intravenously on day 0. Solid lines: no
treatment after L10 injection intravenously. Broken lines: Treated with 750 pg BCG CW and 106
irradiated LIO cells on day 2 (left flank) and day 9 (right flank). The fractions indicate the number
of animals alive and tumor-free/number tested. (Two treated animals in A died tumor-free: one on
day 118 and one on day 120, and have been excluded from the analysis. The other two treated
animals that died in A and B were not necropsied to confirm the presence of tumor. Necropsies were
also not performed on three untreated animals [two in B and one in C1. All other animals that died
had multiple lung tumors. In addition, seven had penile tumors [two in B and five in C1.)
In previous experiments, immunotherapy was given after excision of the primary
dermal tumor at a stage when there were micrometastases only in the first draining
(SDA) lymph node and no detectable immunity to tumor challenge (1, 2, 12) . In the
present report, we tested immunotherapy after the development of palpable metastasis
in the first lymph node and dissemination of microscopic metastases to more distant
sites. Residual micrometastases grew even though at this stage of the disease, tumor
rejection immunity was detectable. The detection of tumor rejection immunity at this
stage of disease confirms previous reports (12, 13, 14) . Occult metastases could be
eradicated in most treated animals when surgery was followed by two treatments with
BCG CW mixed with 108 irradiated L10 cells.
There was some indication that animals that had developed palpable lymph node
metastases had impaired ability to respond to therapy. Thus, we found, they were
afforded little protection by a single treatment with vaccines that were previously
shown to be effective against micrometastases in the SDA lymph node (2) . They were
also less able to resist the outgrowth of tumor cells from injection sites containing a
mixture of L10 cells and adjuvant. Whether or not this reflects an immunological
impairment of the host has not been established.HUNTER ET AL .
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Ftc . 3. Therapy of pulmonary tumor deposits with vaccines containing irradiated L10 cells.
Animals received 106 LIO cells intravenously on day 0, and received : no treatment (" ), vaccination
on day 1 and 8 (O), vaccination on days 4 and 11 (O), and vaccination on days 7 and 14 (A) .
Vaccination consisted of injection of 750 lag BCG CW and 10 6 irradiated L10 cells intradermally,
first on the left flank, and 7 d later on the right flank . A control group with animals treated with
BCG CW only on days 1 and 8 (/) was included. (There were 10 animals per group . All control
animals that received tumor intravenously died with multiple tumor nodules in the lungs . One
animal treated with vaccine on days 1 and 8 died with penile tumors as well as multiple tumor
nodules in the lung on day 103 . Three animals treated with vaccine on days 4 and 7 died with
ascites tumor and intra-abdominal lymph node metastases ; an additional animal died tumor-free
on day 102. Four animals treated on day 7 and 15 died with penile tumors as well as multiple tumor
nodules in the lung. All but one ofthe animals treated withBCGCW alone died with penile tumors
and multiple tumor nodules in the lungs . The remaining animals that died were found to have
tumor nodules in the lungs only.)
We studied the effect of specific immunization on intravenously established pul-
monary tumor deposits by intravenous injection of L10 tumor cells . Metastasis from
dermal L10 tumors occurs primarily by the lymphatic route, although hematogenous
lung metastases occur after extensive growth of lymph node metastases (3) . Hanna
and Peters (6) and Bartlett et al . (15) have shown that the outgrowth ofintravenously
injected L10 can be prevented by immunization with irradiated tumor cells plus live
BCG . In this study, we found that immunization with a mixture of x-irradiated L10
cells and BCGCW as adjuvant could eradicate pulmonary tumor deposits implanted
intravenously in the lungs of normal guinea pigs . Immunization was also effective in
postsurgical therapy of animals with pulmonary tumor deposits and microscopic PA
lymph node metastases .
The therapeutic efficacy of surgery and active immunization for animals with stage
II and III disease offers some hope that analogous treatment may be effective for
humans with stage III cancer, provided that human malignant neoplasms contain
appropriate antigens . The hope for therapy of stage III disease must be tempered
because in this and other studies (6), pulmonary tumor deposits were introduced at a
time when animals were at clinical stage I or stage 11 and, therefore may have been
in a better state of health than would have been animals with stage III disease arising
as a consequence of the dermal implant . Experiments are in progress in which the
therapeutic efficacy ofsurgery and active immunization is being tested for animals at
stage III without intravenously implanted tumor deposits .260
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TABLE II
Postsurgical Immunotherapy of Microscopic Lymph Node and Lung
Metastases
Receivedfor publication 16 March 1981 .
* Experiment was observed for 220 d after intradermal (i.d .) injection ofL10 .
106 L10 cells injected intraperitoneally or 105 cells injected intravenously
(i .v .) .
§ 750 g,g BCG CW + 106 irradiated L10 cells given ipsilaterally on day 22
and contralaterally on day 29.
~~ Excision of dermal tumor and SDA lymph node .
Excision of dermal tumor, fore limb, and the SDA, PA, FRA, and SDC
lymph nodes .
** One animal died tumor-free 73 d after i.d . tumor implantation .
$$ One animal died tumor-free 106 d after i .v . injection of tumor .
§§ One animal died tumor-free 124 d after i.d. tumor implantation . P = 0.037
vs . controls receiving no vaccine.
One animal died tumor-free 98 d after i.d. implantation of tumor . P =
0.007 vs . controls receiving no vaccine .
~~ Vaccine divided between all four quadrants on both days 22 and 29 . P =
0.002 vs . controls receiving no vaccine .
Summary
The malignant disease produced in guinea pigs by intradermal inoculation of line-
10 was allowed to progress to stage II, at which time the dermal tumor and the first
draining lymph node were grossly evident . At that stage, the external appearance of
the next draining lymph node was normal, but it contained tumor cells . Limited
surgery consisting of excision of the dermal tumor and first draining lymph node was
not curative ; palpable metastases developed in the second and other draining lymph
nodes, and at autopsy, some animals were found to have gross, visible lung metastases .
Immunization of guinea pigs with a mixture of irradiated syngeneic tumor cells
plus mycobacterial cell walls in an oil-in-water emulsion eradicated tumor cells
remaining in lymph nodes after limited surgery for stage II experimental cancer and
prevented progression of the disease to stage III . Tumor intravenously implanted in
the lungs of animals after limited surgery for stage II disease was also eliminated by
immunization .
We thank Mr. Marion Taylor of the LIB, DCBD, and the staff of Building 571, Frederick
Cancer Research Center, for their excellent technical assistance .
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